DK1408961T3 - 2 pyrrolidon-derivater som prostanoide agonister - Google Patents

2 pyrrolidon-derivater som prostanoide agonister

Info

Publication number
DK1408961T3
DK1408961T3 DK02762347T DK02762347T DK1408961T3 DK 1408961 T3 DK1408961 T3 DK 1408961T3 DK 02762347 T DK02762347 T DK 02762347T DK 02762347 T DK02762347 T DK 02762347T DK 1408961 T3 DK1408961 T3 DK 1408961T3
Authority
DK
Denmark
Prior art keywords
pyrrolidone derivatives
prostanoid
prostanoid agonists
agonists
pyrrolidone
Prior art date
Application number
DK02762347T
Other languages
English (en)
Inventor
Todd Richard Elworthy
Michael Garret Roepel
David Bernard Smith
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK1408961T3 publication Critical patent/DK1408961T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
DK02762347T 2001-07-16 2002-07-11 2 pyrrolidon-derivater som prostanoide agonister DK1408961T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30576201P 2001-07-16 2001-07-16
PCT/EP2002/007733 WO2003007941A1 (en) 2001-07-16 2002-07-11 2 pyrrolidone derivatives as prostanoid agonists

Publications (1)

Publication Number Publication Date
DK1408961T3 true DK1408961T3 (da) 2007-11-05

Family

ID=23182225

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02762347T DK1408961T3 (da) 2001-07-16 2002-07-11 2 pyrrolidon-derivater som prostanoide agonister

Country Status (20)

Country Link
US (1) US6849657B2 (da)
EP (1) EP1408961B1 (da)
JP (2) JP4211605B2 (da)
KR (1) KR100702368B1 (da)
CN (1) CN100371322C (da)
AT (1) ATE366571T1 (da)
AU (1) AU2002328338C1 (da)
BR (1) BR0211167A (da)
CA (1) CA2451393C (da)
DE (1) DE60221130T2 (da)
DK (1) DK1408961T3 (da)
ES (1) ES2289140T3 (da)
GT (1) GT200200152A (da)
MX (1) MXPA04000454A (da)
PA (1) PA8550501A1 (da)
PE (1) PE20030286A1 (da)
PL (1) PL215425B1 (da)
PT (1) PT1408961E (da)
RU (1) RU2296122C2 (da)
WO (1) WO2003007941A1 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0211167A (pt) * 2001-07-16 2004-08-10 Hoffmann La Roche Derivados de 2-pirrolidona como agonistas de prostanóides
MXPA04000757A (es) * 2001-07-23 2004-07-08 Ono Pharmaceutical Co Remedios para enfermedades con perdida de masa de hueso que tienen agonistas ep4 como ingrediente activo.
EP1453503A4 (en) * 2001-12-03 2005-03-30 Merck & Co Inc EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS
JP4547912B2 (ja) 2002-03-05 2010-09-22 小野薬品工業株式会社 ８−アザプロスタグランジン誘導体化合物およびその化合物を有効成分として含有する薬剤
US6573294B1 (en) 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
EP1556347A4 (en) 2002-06-10 2006-08-09 Applied Research Systems GAMMA LACTAME AS PROSTAGLAND INAGONISTS AND THEIR USE
CA2511255C (en) * 2003-01-10 2009-04-07 F. Hoffmann-La Roche Ag 2-piperidone derivatives as prostaglandin agonists
JP4662926B2 (ja) 2003-03-03 2011-03-30 メルク セローノ ソシエテ アノニム プロスタグランジン作動薬としてのγ−ラクタム誘導体
US6734201B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents
US6734206B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
US7435746B2 (en) * 2004-06-04 2008-10-14 Allergan, Inc. 5-thiopiperdinyl prostaglandin E analogs
ES2336933T3 (es) 2004-12-06 2010-04-19 Merck Serono Sa Derivados de pirrolidin-2-ona para usar como antagonistas del receptor dp1.
US7531533B2 (en) 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
AU2006209543B2 (en) * 2005-01-27 2009-04-30 Asahi Kasei Pharma Corporation Six-membered heterocyclic compound and the use thereof
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8372912B2 (en) * 2005-08-12 2013-02-12 Eastman Chemical Company Polyvinyl chloride compositions
US8088854B2 (en) * 2006-08-30 2012-01-03 Eastman Chemical Company Terephthalates as plasticizers in vinyl acetate polymer compositions
ES2402470T3 (es) 2006-08-30 2013-05-06 Eastman Chemical Company Composiciones sellantes que tienen un nuevo plastificante
AU2008246579A1 (en) 2007-05-08 2008-11-13 National University Corporation, Hamamatsu University School Of Medicine Cytotoxic T cell activator comprising EP4 agonist
US20120142684A1 (en) * 2010-12-02 2012-06-07 Allergan, Inc. Compounds and methods for skin repair
WO2013018837A1 (ja) 2011-08-02 2013-02-07 小野薬品工業株式会社 左室拡張機能改善剤
CA2879506C (en) 2012-07-19 2020-10-27 Cayman Chemical Company, Inc. Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
CA2903314C (en) 2013-03-15 2023-02-14 Cayman Chemical Company, Inc. Methods of synthesizing a difluorolactam analog
US9676712B2 (en) 2013-03-15 2017-06-13 Cayman Chemical Company, Inc. Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
EA201591793A1 (ru) 2013-03-15 2016-01-29 Кайман Кемикал Компани, Инк. Лактамные соединения в качестве селективных агонистов ep4-рецепторов для применения при лечении опосредованных ep4 заболеваний и состояний
EP3021879A2 (en) 2013-07-19 2016-05-25 Cayman Chemical Company, Incorporated Methods, systems, and compositions for promoting bone growth
EP3733665B1 (en) 2017-12-25 2022-09-28 Asahi Kasei Pharma Corporation 2-oxo-1,3,4-thiadiazinan-3-yl moiety containing compounds with ep4 receptor agonist activity

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3975399A (en) 1974-08-06 1976-08-17 E. I. Du Pont De Nemours And Company 1,5-Disubstituted-2-pyrrolidinones, -3-pyrrolin-2-ones, and -4-pyrrolin-2-ones
US4113873A (en) 1975-04-26 1978-09-12 Tanabe Seiyaku Co. Ltd. 8-azaprostanoic acid derivatives
NL7604330A (nl) * 1975-04-28 1976-11-01 Syntex Inc Werkwijze voor de bereiding van 8-azaprostaan- zuurderivaten.
DE2528664A1 (de) 1975-06-27 1977-01-13 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
DE2556326A1 (de) 1975-12-13 1977-06-23 Hoechst Ag Neue pyrrolidone und verfahren zu ihrer herstellung
IL49325A (en) 1976-03-31 1979-11-30 Labaz 8-aza-11-deoxy-pge1 derivatives,their preparation and pharmaceutical compositions containing them
DE2619638A1 (de) 1976-05-04 1977-11-17 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
US4177346A (en) 1976-08-06 1979-12-04 Pfizer Inc. 1,5-Disubstituted-2-pyrrolidones
US4320136A (en) 1980-08-11 1982-03-16 E. I. Du Pont De Nemours And Company 8-Aza-16,16-difluoroprostanoids
JP2571250B2 (ja) * 1987-01-19 1997-01-16 三共株式会社 プロスタグランジン化合物
SE9702681D0 (sv) * 1997-07-10 1997-07-10 Pharmacia & Upjohn Ab Method and composition for treatment of impotence
TWI249520B (en) * 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
WO2000021542A1 (en) 1998-10-15 2000-04-20 Merck & Co., Inc. Methods for stimulating bone formation
CA2346038A1 (en) 1998-10-15 2000-04-20 Merck & Co., Inc. Methods for inhibiting bone resorption
US6211226B1 (en) * 1998-12-17 2001-04-03 Alcon Laboratories, Inc. 11-Aza prostaglandins for the treatment of glaucoma and ocular hypertension
TWI247606B (en) * 1999-11-24 2006-01-21 Ono Pharmaceutical Co Treating agent for osteopenic diseases
AU1293101A (en) 1999-12-22 2001-07-03 Pfizer Products Inc. Ep4 receptor selective agonists in the treatment of osteoporosis
DK1132086T3 (da) * 2000-01-31 2006-08-28 Pfizer Prod Inc Anvendelse af prostaglandin (PGE2) selektive receptor 4 (EP4) agonister til behandling af akut og kronisk nyresvigt
AU2001235990A1 (en) * 2000-02-28 2001-09-03 Fumie Sato Prostaglandin e derivatives
WO2002024647A1 (fr) 2000-09-21 2002-03-28 Ono Pharmaceutical Co., Ltd. Agonistes du recepteur de l'ep4 comprenant comme principe actif des derives de la 8-azaprostaglandine
CA2429850C (en) * 2000-11-27 2008-12-30 Pfizer Products Inc. Ep4 receptor selective agonists in the treatment of osteoporosis
BR0211167A (pt) * 2001-07-16 2004-08-10 Hoffmann La Roche Derivados de 2-pirrolidona como agonistas de prostanóides

Also Published As

Publication number Publication date
MXPA04000454A (es) 2004-03-18
CA2451393A1 (en) 2003-01-30
EP1408961A1 (en) 2004-04-21
CA2451393C (en) 2011-01-04
US20030064964A1 (en) 2003-04-03
PA8550501A1 (es) 2003-06-30
WO2003007941A1 (en) 2003-01-30
GT200200152A (es) 2003-06-19
DE60221130T2 (de) 2008-03-13
ATE366571T1 (de) 2007-08-15
CN100371322C (zh) 2008-02-27
KR20040017317A (ko) 2004-02-26
PE20030286A1 (es) 2003-03-25
PT1408961E (pt) 2007-10-10
BR0211167A (pt) 2004-08-10
AU2002328338B2 (en) 2008-04-24
JP5003601B2 (ja) 2012-08-15
RU2296122C2 (ru) 2007-03-27
US6849657B2 (en) 2005-02-01
PL367696A1 (en) 2005-03-07
RU2004104627A (ru) 2005-07-10
PL215425B1 (pl) 2013-12-31
JP2008303222A (ja) 2008-12-18
DE60221130D1 (de) 2007-08-23
AU2002328338C1 (en) 2009-01-08
ES2289140T3 (es) 2008-02-01
CN1529593A (zh) 2004-09-15
EP1408961B1 (en) 2007-07-11
JP4211605B2 (ja) 2009-01-21
JP2004538280A (ja) 2004-12-24
KR100702368B1 (ko) 2007-04-02

Similar Documents

Publication Publication Date Title
DK1408961T3 (da) 2 pyrrolidon-derivater som prostanoide agonister
CY1111876T1 (el) Νεες πυρρολες με υπολiπiδaiμiκες και υποχοληστερολαιμικες δραστικοτητες, μεθοδος για την παρασκευη αυτων και φαρμακευτικες συνθεσεις που τις περιεχουν και η χρηση αυτων στην ιατρικη
NO20041504L (no) Lactamderivater som antagonister for humane 11CBY reseptorer.
ATE297910T1 (de) Retinoid x rezeptormodulatoren
CY1109015T1 (el) Διφαινυλ ενωσεις χρησιμες ως ανταγωνιστες μουσκαρινικου υποδοχεα
DE60210944D1 (de) N-substituierte heterocyclische nichtaryl-nmda/nr2b-antagonisten
ATE496620T1 (de) 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
SE0303180D0 (sv) Novel compounds
SE0302232D0 (sv) Novel Compounds
HK1061649A1 (en) N-(2-arylethyl) benzylamines as antagonists of the5-ht6 receptor
MY143834A (en) Thrombin receptor antagonists
EA200700365A1 (ru) Производные индол-2-карбоксамидина как антагонисты nmda рецептора
DE602004009200D1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
DE602006017837D1 (de) Azabicycloä3.1.0ühexan-derivate als modulatoren des dopamin-d3-rezeptors
EA200200774A1 (ru) Новые соединения, обладающие гиполипидемической, гипохолестеринемической активностью, способ их получения и содержащие их композиции
EA200600694A1 (ru) Дисульфидные, сульфидные, сульфоксидные и сульфоновые производные циклических сахаров и их применение
DE60336735D1 (de) Neue biologischaktive molekü le
DK1448562T3 (da) Substituerede tetracycliske pyrroloquinolonderivater egnede som phosphodiesteraseinhibitorer
UA84896C2 (ru) Производные гидронопола как агонисты человеческих рецепторов orl1
EA200700246A1 (ru) Трициклические производные пиразола в качестве модуляторов каннабиноидного рецептора
NO20062249L (no) 1H-imidazolderivater som cannabionidreseptor modulatorer
DK1673354T3 (da) Arylindenopyridiner og arylindenopyrimidiner og deres anvendelse som adenosin-A2a-receptorantagonister
NO20044473L (no) Ikke-steroidal progesteron reseptor modulatorer
DE602007003207D1 (de) Heterocyclische modulatoren für den gaba-alpha-subtyp-selektiven rezeptor
ATE405544T1 (de) Tyrosinderivate als ppar-gamma-modulatoren